CNBCLean R·
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Read at CNBC →
Business · 1 sources covering this
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
Coverage spectrum
0 L · 0 C · 1 R
How 1 sources are covering this
Embed this bias spectrum on your site
Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.
<iframe src="https://statesidedaily.com/embed/cluster/4a5cca5406133db74e0ca2b16f18f7f862755e3c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again"></iframe>
